RS65104B1 - Onkolitičke imunoterapije - Google Patents
Onkolitičke imunoterapijeInfo
- Publication number
- RS65104B1 RS65104B1 RS20240082A RSP20240082A RS65104B1 RS 65104 B1 RS65104 B1 RS 65104B1 RS 20240082 A RS20240082 A RS 20240082A RS P20240082 A RSP20240082 A RS P20240082A RS 65104 B1 RS65104 B1 RS 65104B1
- Authority
- RS
- Serbia
- Prior art keywords
- immuno
- oncolytic therapies
- oncolytic
- therapies
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361868978P | 2013-08-22 | 2013-08-22 | |
| EP20189155.3A EP3778897B1 (en) | 2013-08-22 | 2014-08-22 | Immuno-oncolytic therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS65104B1 true RS65104B1 (sr) | 2024-02-29 |
Family
ID=52484194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20240082A RS65104B1 (sr) | 2013-08-22 | 2014-08-22 | Onkolitičke imunoterapije |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11478518B2 (sr) |
| EP (3) | EP4324918A3 (sr) |
| JP (3) | JP6912199B2 (sr) |
| KR (1) | KR102389240B1 (sr) |
| CN (1) | CN105658795B (sr) |
| AU (1) | AU2014308648B2 (sr) |
| CA (3) | CA2921041C (sr) |
| DK (2) | DK3036329T3 (sr) |
| EA (1) | EA037582B1 (sr) |
| ES (2) | ES2971528T3 (sr) |
| FI (1) | FI3778897T3 (sr) |
| HK (1) | HK1223402A1 (sr) |
| HR (1) | HRP20240078T1 (sr) |
| IL (1) | IL243996A0 (sr) |
| LT (1) | LT3778897T (sr) |
| MD (2) | MD4624C1 (sr) |
| MX (1) | MX2016002257A (sr) |
| NZ (1) | NZ716825A (sr) |
| PE (1) | PE20160673A1 (sr) |
| PH (1) | PH12016500329A1 (sr) |
| PL (1) | PL3778897T3 (sr) |
| PT (1) | PT3778897T (sr) |
| RS (1) | RS65104B1 (sr) |
| SG (1) | SG11201600960PA (sr) |
| SI (1) | SI3778897T1 (sr) |
| WO (1) | WO2015027163A1 (sr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4324918A3 (en) * | 2013-08-22 | 2024-04-24 | University of Pittsburgh - of The Commonwealth System of Higher Education | Immuno-oncolytic therapies |
| EP3261669B1 (en) | 2015-02-25 | 2022-08-03 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| CN116173193A (zh) | 2015-04-17 | 2023-05-30 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
| EP3327137B1 (en) * | 2015-07-22 | 2020-12-09 | National University Corporation Tottori University | Host regulation factor for enhancing proliferation and propagation of vaccinia virus |
| CA2996120C (en) * | 2015-09-08 | 2024-02-20 | Sillajen, Inc. | Modified oncolytic vaccinia viruses expressing a cytokine and a carboxylesterase and methods of use thereof |
| AU2016349632A1 (en) | 2015-11-07 | 2018-05-24 | Multivir Inc. | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| SG11201807022XA (en) | 2016-02-25 | 2018-09-27 | Memorial Sloan Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
| EP3419648A4 (en) | 2016-02-25 | 2019-09-11 | Memorial Sloan-Kettering Cancer Center | ATTENUATED REPLICATION-VACCINE VIRUSES WITH THYMIDINE KINASE DELETION WITH AND WITHOUT EXPRESSION OF FLT3L OR HUMAN GM-CSF FOR ANTICANCER IMMUNOTHERAPY |
| KR20190007416A (ko) * | 2016-03-25 | 2019-01-22 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 합성적으로 엔벨롭된 바이러스 |
| EP3254692A1 (en) * | 2016-06-10 | 2017-12-13 | Ceva Sante Animale | Multivalent recombinant spv |
| CA3070146A1 (en) | 2016-07-19 | 2018-01-25 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oncolytic viruses targeting stat3 |
| JP2019528753A (ja) * | 2016-09-21 | 2019-10-17 | スティーブン エイチ． ソーン， | 高移動度グループｂｏｘｉ突然変異体 |
| GB201616365D0 (en) * | 2016-09-27 | 2016-11-09 | Helsingin Yliopisto | Non-genetic modification of enveloped viruses |
| WO2018111902A1 (en) | 2016-12-12 | 2018-06-21 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| AU2018215558B2 (en) * | 2017-02-03 | 2023-05-25 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Oncolytic virus therapy |
| US20180252729A1 (en) * | 2017-03-06 | 2018-09-06 | University Of Louisville Research Foundation | Methods and compositions for determining the potency of a therapeutic cellular composition |
| AU2018254626B2 (en) * | 2017-04-21 | 2023-12-21 | Sillajen, Inc. | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy |
| EP3621646A4 (en) | 2017-05-12 | 2021-06-02 | Memorial Sloan Kettering Cancer Center | VACCINIA VIRUS MUTANTS FOR CANCER IMMUNOTHERAPY |
| US12036257B2 (en) | 2017-10-31 | 2024-07-16 | Kalivir Immunotherapeutics, Inc. | Platform oncolytic vector for systemic delivery |
| JP2021503965A (ja) | 2017-12-01 | 2021-02-15 | スッター，ゲルド | 複製効率の高い免疫調節ワクシニアウイルス株 |
| KR20200121297A (ko) * | 2018-01-05 | 2020-10-23 | 오타와 하스피털 리서치 인스티튜트 | 변형된 오르토폭스바이러스 벡터 |
| KR20200135986A (ko) | 2018-03-19 | 2020-12-04 | 멀티비르 인코포레이티드 | 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물 |
| WO2020018996A2 (en) * | 2018-07-20 | 2020-01-23 | Ansun Biopharma, Inc. | Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment |
| US20220056480A1 (en) * | 2018-12-21 | 2022-02-24 | Ottawa Hospital Research Institute | Modified orthopoxvirus vectors |
| SG11202107017TA (en) * | 2019-01-07 | 2021-07-29 | Kalivir Immunotherapeutics Inc | Methods of treating cancer |
| US11529402B2 (en) * | 2019-01-14 | 2022-12-20 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| CA3129883A1 (en) | 2019-02-14 | 2020-08-20 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| KR20220082025A (ko) * | 2019-10-16 | 2022-06-16 | 칼리버 임뮤노쎄라퓨틱스, 인크. | 변형된 세포외 외피보유 바이러스 |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| IL293627A (en) * | 2019-12-12 | 2022-08-01 | Ignite Immunotherapy Inc | Variant of oncolytic vaccinia virus and methods of using it |
| MX2022008547A (es) * | 2020-01-09 | 2022-08-10 | Pfizer | Virus de vacuna recombinante. |
| BR112023022681A2 (pt) | 2021-04-30 | 2024-01-23 | Kalivir Immunotherapeutics Inc | Vírus oncolíticos para expressão modificada de mhc |
| EP4363059A1 (en) * | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2023106839A1 (ko) * | 2021-12-07 | 2023-06-15 | 재단법인 아산사회복지재단 | Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120002613A (ko) * | 2002-08-12 | 2012-01-06 | 제네렉스, 인코포레이티드 | 폭스바이러스 및 암과 관련된 방법 및 조성물 |
| WO2007023725A1 (ja) * | 2005-08-25 | 2007-03-01 | Yokohama City University | 遺伝子ワクチン |
| US9180149B2 (en) * | 2005-09-07 | 2015-11-10 | Sillajen Biotherapeutics, Inc. | Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses |
| AU2012244210B2 (en) * | 2005-09-07 | 2014-10-02 | Sillajen Biotherapeutics, Inc. | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
| US8980246B2 (en) * | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
| KR20080084528A (ko) | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| WO2009124044A2 (en) * | 2008-03-31 | 2009-10-08 | University Of Florida Research Foundation, Inc. | Tumor growth inhibition via conditioning of tumor microenvironment |
| EP3409119B1 (en) | 2009-09-14 | 2020-08-12 | SillaJen Biotherapeutics, Inc. | Oncolytic vaccinia virus combination cancer therapy |
| WO2011119925A2 (en) * | 2010-03-25 | 2011-09-29 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthetic herpes simplex viruses for treatment of cancers |
| CN114262690A (zh) * | 2011-04-15 | 2022-04-01 | 吉恩勒克斯公司 | 减毒的痘苗病毒的克隆毒株及其使用方法 |
| US20150250837A1 (en) * | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| EP4324918A3 (en) | 2013-08-22 | 2024-04-24 | University of Pittsburgh - of The Commonwealth System of Higher Education | Immuno-oncolytic therapies |
-
2014
- 2014-08-22 EP EP23215391.6A patent/EP4324918A3/en active Pending
- 2014-08-22 HR HRP20240078TT patent/HRP20240078T1/hr unknown
- 2014-08-22 MD MD20160027A patent/MD4624C1/ro active IP Right Grant
- 2014-08-22 CA CA2921041A patent/CA2921041C/en active Active
- 2014-08-22 LT LTEP20189155.3T patent/LT3778897T/lt unknown
- 2014-08-22 PL PL20189155.3T patent/PL3778897T3/pl unknown
- 2014-08-22 KR KR1020167006785A patent/KR102389240B1/ko active IP Right Grant
- 2014-08-22 PT PT201891553T patent/PT3778897T/pt unknown
- 2014-08-22 FI FIEP20189155.3T patent/FI3778897T3/fi active
- 2014-08-22 DK DK14837931.6T patent/DK3036329T3/da active
- 2014-08-22 DK DK20189155.3T patent/DK3778897T3/da active
- 2014-08-22 EA EA201690444A patent/EA037582B1/ru unknown
- 2014-08-22 MX MX2016002257A patent/MX2016002257A/es unknown
- 2014-08-22 SI SI201432060T patent/SI3778897T1/sl unknown
- 2014-08-22 NZ NZ716825A patent/NZ716825A/en unknown
- 2014-08-22 EP EP20189155.3A patent/EP3778897B1/en active Active
- 2014-08-22 CA CA3213683A patent/CA3213683A1/en active Pending
- 2014-08-22 CA CA3213715A patent/CA3213715A1/en active Pending
- 2014-08-22 ES ES20189155T patent/ES2971528T3/es active Active
- 2014-08-22 PE PE2016000287A patent/PE20160673A1/es unknown
- 2014-08-22 RS RS20240082A patent/RS65104B1/sr unknown
- 2014-08-22 WO PCT/US2014/052308 patent/WO2015027163A1/en active Application Filing
- 2014-08-22 EP EP14837931.6A patent/EP3036329B1/en active Active
- 2014-08-22 JP JP2016536482A patent/JP6912199B2/ja active Active
- 2014-08-22 SG SG11201600960PA patent/SG11201600960PA/en unknown
- 2014-08-22 MD MDA20180086A patent/MD4748C1/ro active IP Right Grant
- 2014-08-22 ES ES14837931T patent/ES2847305T3/es active Active
- 2014-08-22 AU AU2014308648A patent/AU2014308648B2/en active Active
- 2014-08-22 CN CN201480058401.0A patent/CN105658795B/zh active Active
-
2016
- 2016-02-07 IL IL243996A patent/IL243996A0/en unknown
- 2016-02-18 PH PH12016500329A patent/PH12016500329A1/en unknown
- 2016-02-19 US US15/048,698 patent/US11478518B2/en active Active
- 2016-10-12 HK HK16111742.0A patent/HK1223402A1/zh unknown
-
2019
- 2019-07-19 JP JP2019133264A patent/JP7021154B2/ja active Active
-
2022
- 2022-02-03 JP JP2022015459A patent/JP7333431B2/ja active Active
- 2022-09-07 US US17/939,707 patent/US20230008089A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1223402A1 (zh) | 免疫溶瘤療法 | |
| DK3689865T3 (en) | Hidtil ukendte aminopyrimidinderivater | |
| DK3088517T3 (en) | Humant anti-il-33-neutraliserende monoklonalt antistof | |
| DK3736291T3 (en) | Anti-FCRH5-antistoffer | |
| DK3354246T3 (en) | Udstyrsmonteringssystem | |
| DK3077519T3 (en) | Cmv-vacciner | |
| EP3000028A4 (en) | AUTOMATIC ADDING TO AN AGENDA | |
| EP2957205A4 (en) | HAND DRYER | |
| DK3470074T3 (en) | Probiotika | |
| AU353576S (en) | Stamphousing | |
| DK3056208T3 (en) | Immunpotentiator | |
| DK2979701T3 (en) | Antitumormiddel indbefattende irinotecanhydrochloridhydrat | |
| EP3014557A4 (en) | TELEPHONE ON FILE | |
| GB201300001D0 (en) | Envirep - environment replicater | |
| DK2989854T3 (en) | Strømstyret opvarmningssystem | |
| AU4953P (en) | Flogazora Gazania rigens | |
| AU4977P (en) | Harrosy Gaura lindheimeri | |
| GB201320265D0 (en) | GreetGate | |
| AU353330S (en) | Kettlebell | |
| AU353331S (en) | Kettlebell | |
| AU353329S (en) | Kettlebell | |
| AU353328S (en) | Kettlebell | |
| AU353327S (en) | Kettlebell | |
| AU353325S (en) | Kettlebell | |
| AP00812S1 (en) | Stumbelbloc |